Health Trials

Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

1

Review clinical trials related to Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

This study is a randomized, open-label Phase 2 study to compare the efficacy and safety of IBI363 Combined with Chemotherapy or Pembrolizumab Combined with Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer.

Participants needed: 170
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Innovent Biologics (Suzhou) Co. Ltd.Updated: Sep 30, 2025Locations: 1
Eligibility criteria

Males and Females, age ≥18 years and ≤75 years; [+7]

Histologically confirmed the presence of small cell lung cancer, neuroendocrine... [+12]

Read more